Live Breaking News & Updates on Director Daniel Bradbury

Stay updated with breaking news from Director daniel bradbury. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $138,118.75 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) Director Daniel Bradbury sold 6,875 shares of the company’s stock in a transaction that occurred on Friday, December 8th. The shares were sold at an average price of $20.09, for a total transaction of $138,118.75. Following the completion of the sale, the director now directly owns 50,605 […] ....

Daniel Bradbury , Castle Biosciences , Castle Biosciences Inc , Royal Bank , Assetmark Inc , Bluepath Capital Management , Tower Research Capital , Osaic Holdings Inc , Securities Exchange Commission , Get Free Report , Director Daniel Bradbury , Exchange Commission , Path Capital Management , Research Capital , Castle Biosciences Daily , Nasdaq Cstl , Insider Trading , Nsider Trades ,

Castle Biosciences (NASDAQ:CSTL) Now Covered by Guggenheim

Stock analysts at Guggenheim began coverage on shares of Castle Biosciences (NASDAQ:CSTL – Get Free Report) in a note issued to investors on Thursday, Briefing.com reports. The brokerage set a “buy” rating and a $25.00 price target on the stock. Guggenheim’s target price would suggest a potential upside of 21.65% from the company’s previous close. […] ....

Castle Biosciences , Daniel Bradbury , Derekj Maetzold , Royal Bank , Tower Research Capital , Securities Exchange Commission , Osaic Holdings Inc , Castle Biosciences Inc , Castle Biosciences Company Profile , Lazard Asset Management , Bluepath Capital Management , Get Free Report , Director Daniel Bradbury , Exchange Commission , Path Capital Management , Research Capital , Castle Biosciences Daily , Nasdaq Cstl , Initiated Coverage ,

Castle Biosciences, Inc. (NASDAQ:CSTL) Director Sells $191,377.25 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) Director Daniel Bradbury sold 9,545 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $20.05, for a total value of $191,377.25. Following the transaction, the director now owns 54,502 shares of the company’s stock, valued at […] ....

Castle Biosciences , Daniel Bradbury , Assetmark Inc , Royal Bank , Osaic Holdings Inc , Castle Biosciences Company Profile , Tower Research Capital , Castle Biosciences Inc , Bluepath Capital Management , Get Free Report , Director Daniel Bradbury , Path Capital Management , Research Capital , Castle Biosciences Daily , Nasdaq Cstl , Insider Trading , Nsider Trades ,

Castle Biosciences, Inc. (NASDAQ:CSTL) Stock Holdings Lifted by Portolan Capital Management LLC

Portolan Capital Management LLC lifted its position in Castle Biosciences, Inc. (NASDAQ:CSTL – Free Report) by 68.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 431,474 shares of the company’s stock after acquiring an additional 174,825 shares during the […] ....

Derekj Maetzold , Daniel Bradbury , Castle Biosciences , Nisa Investment Advisors , Castle Biosciences Company Profile , Castle Biosciences Inc , Securities Exchange Commission , Tower Research Capital , Exchange Commission , Lazard Asset Management , Assetmark Inc , Ensign Peak Advisors Inc , Portolan Capital Management , Free Report , Capital Management , Investment Advisors , Asset Management , Research Capital , Peak Advisors Inc , Get Free Report , Director Daniel Bradbury , Castle Biosciences Daily , Nasdaq Cstl , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,